Methods for modifying genomic DNA

Inventors

Li, Linhong • Peshwa, Madhusudan

Assignees

Maxcyte Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11608511-B2

Patent

Publication Date

2023-03-21

Expiration Date


Abstract

Compositions and methods concern the sequence modification of an endogenous genomic DNA region. Certain aspects relate to a method for site-specific sequence modification of a target genomic DNA region in cells comprising: contacting the cells with an activating composition; transfecting the cells with a transfection composition comprising (a) donor DNA and (b) a DNA digesting agent; wherein the donor DNA comprises: (i) a homologous region comprising nucleic acid sequence homologous to the target genomic DNA region; and (ii) a sequence modification region; and wherein the genomic DNA sequence is modified specifically at the target genomic DNA region.

Core Innovation

The invention relates to an in vitro method for site-specific transgene insertion into a target genomic DNA region in isolated mammalian T cells. The method includes contacting the T cells with an activating composition comprising anti-CD3 and anti-CD28 antibodies to produce activated T cells, and transfecting the activated T cells by electroporation using a non-viral transfection composition.

The non-viral transfection composition includes a donor plasmid DNA, a mRNA encoding a Cas9 DNA digesting agent, and a guide RNA. The donor plasmid DNA comprises a homologous region comprising nucleic acid sequence homologous to the target genomic DNA region, and a transgene of 500-5000 nucleic acids in length. The genomic DNA sequence is modified specifically at the target genomic DNA region.

The method provides stable transgene expression six days after transfection without selection medium. The disclosure further supports CAR integration as an example of the transgene, and describes an in vitro, site-specific transgene insertion workflow in isolated mammalian T cells.

Claims Coverage

The independent claim is clm-00001 and includes four inventive features. It combines cell activation with anti-CD3 and anti-CD28, non-viral electroporation using donor plasmid DNA together with Cas9 DNA digesting agent mRNA and a guide RNA, donor plasmid design with a homologous region and a 500-5000 nucleic-acid transgene, and site-specific genomic modification producing stable transgene expression without selection medium.

Anti-CD3 and anti-CD28 activation

Contacting isolated mammalian T cells with an activating composition comprising anti-CD3 and anti-CD28 antibodies to produce activated T cells.

Non-viral electroporation with donor plasmid DNA, Cas9 mRNA, and guide RNA

Transfecting the activated T cells by electroporation using a non-viral transfection composition comprising donor plasmid DNA, a mRNA encoding a Cas9 DNA digesting agent, and a guide RNA.

Donor plasmid with homologous region and 500-5000-nucleic-acid transgene

The donor plasmid DNA comprises a homologous region comprising nucleic acid sequence homologous to the target genomic DNA region and a transgene of 500-5000 nucleic acids in length.

Site-specific genomic modification with stable expression without selection medium

The genomic DNA sequence is modified specifically at the target genomic DNA region such that stable transgene expression is provided six days after transfection without selection medium.

The independent claim centers on in vitro, site-specific transgene insertion in isolated mammalian T cells by combining anti-CD3 and anti-CD28 activation with non-viral electroporation of donor plasmid DNA, Cas9 DNA digesting agent mRNA, and a guide RNA, together with donor plasmid homology and transgene length features that support stable expression without selection medium.

Stated Advantages

Stable transgene expression six days after transfection without selection medium.

Documented Applications

CAR integration is described as an example of the transgene insertion approach.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.